๐๐๐-๐-๐๐๐ฅ๐ฅ ๐ฌ๐ก๐จ๐ฐ๐ฌ ๐ฉ๐ซ๐จ๐ฆ๐ข๐ฌ๐ ๐ข๐ง ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐ฅ๐ฒ๐ฆ๐ฉ๐ก๐จ๐ฆ๐ ๐จ๐ ๐ญ๐ก๐ ๐๐ซ๐๐ข๐ง ๐๐ง๐ ๐ฌ๐ฉ๐ข๐ง๐๐ฅ ๐๐จ๐ซ๐ ๐ข๐ง ๐๐๐ซ๐ฅ๐ฒ ๐ญ๐ซ๐ข๐๐ฅ
๐ผ ๐พ๐ผ๐-๐-๐๐๐ก๐ก ๐ฉ๐๐๐ง๐๐ฅ๐ฎ ๐ ๐ฃ๐ค๐ฌ๐ฃ ๐๐จ ๐๐ญ๐๐๐๐๐ฉ๐๐๐๐ฃ๐ ๐๐๐ก๐ค๐ก๐๐ช๐๐๐ก (๐๐ญ๐-๐๐๐ก) ๐๐จ ๐จ๐๐๐ ๐๐ฃ๐ ๐จ๐๐ค๐ฌ๐จ ๐๐ฃ๐๐ค๐ช๐ง๐๐๐๐ฃ๐ ๐จ๐๐๐ฃ๐จ ๐ค๐ ๐๐๐๐๐๐๐๐ฎ ๐๐ฃ ๐ ๐จ๐ข๐๐ก๐ก ๐ฅ๐๐ก๐ค๐ฉ ๐ฉ๐ง๐๐๐ก ๐๐ฃ๐ซ๐ค๐ก๐ซ๐๐ฃ๐ ๐ฅ๐๐ฉ๐๐๐ฃ๐ฉ๐จ ๐ฌ๐๐ฉ๐ ๐ก๐ฎ๐ข๐ฅ๐๐ค๐ข๐ ๐ค๐ ๐ฉ๐๐ ๐๐ง๐๐๐ฃ ๐๐ฃ๐/๐ค๐ง ๐จ๐ฅ๐๐ฃ๐๐ก ๐๐ค๐ง๐, ๐ฟ๐๐ฃ๐-๐๐๐ง๐๐๐ง ๐พ๐๐ฃ๐๐๐ง ๐๐ฃ๐จ๐ฉ๐๐ฉ๐ช๐ฉ๐ ๐๐ฃ๐ซ๐๐จ๐ฉ๐๐๐๐ฉ๐ค๐ง๐จ ๐ง๐๐ฅ๐ค๐ง๐ฉ ๐๐ฉ ๐ฉ๐๐ 64๐ฉ๐ ๐ผ๐ข๐๐ง๐๐๐๐ฃ ๐๐ค๐๐๐๐ฉ๐ฎ ๐ค๐ ๐๐๐ข๐๐ฉ๐ค๐ก๐ค๐๐ฎ (๐ผ๐๐) ๐ผ๐ฃ๐ฃ๐ช๐๐ก ๐๐๐๐ฉ๐๐ฃ๐.
A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of Hematology (ASH) Annual Meeting.
The research features an in-depth, molecular study of individual CAR-T cells isolated from patientsโ blood and cerebrospinal fluid (CSF), which surrounds the brain and spinal cord. This unprecedented analysis, conducted in collaboration with the Cellular Therapeutics and Systems Immunology Lab (CTSI), directed by Leslie Kean, MD, PhD, at Dana-Farber and Boston Childrenโs Hospital, reveals a surprising difference between the two CAR-T-cell populations: the cells in the CSF display a molecular signature that indicates activation of the interferon pathway, an important step in rallying the immune system. These studies are reported in two oral abstracts at ASH. โFor many patients with lymphoma of the central nervous system, there arenโt great treatment options,โ said Dana-Farberโs Caron Jacobson, MD, MMSc, who led the trial and will present the findings at ASH. โOur early results suggest that expanding the applicability of CAR-T cells to this indication could improve patient outcomes.โ
Lymphomas can begin within the brain or spinal cord, or the tumors can spread to those sites (known collectively as the central nervous system or CNS) after they originate in other parts of the body. While the underlying biology of these primary and secondary CNS lymphomas can be quite different, these cancers are often difficult to treat, especially once the tumors evade standard treatments. In that case, patients typically do not live more than 2 years.
